November 1, 2017 / 7:11 AM / a month ago

BRIEF-Biohaven announces FDA clearance of IND application for sublingual BHV-0223

Nov 1 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd

* Biohaven announces FDA clearance of IND application for sublingual bhv-0223 in patients with amyotrophic lateral sclerosis (ALS)

* ‍U.S. FDA has notified that co may proceed with clinical investigation of sublingual bhv-0223 ​

* Expects to submit an IND to FDA by end of this year for BHV-3500 for treatment of migraine​

* Expects to commence a Bioequivalence study of BHV-0223 in the current quarter Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below